Advertisement
Advertisement
U.S. markets close in 1 hour 58 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Global Blood Therapeutics, Inc. (GBT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
25.66+0.43 (+1.69%)
As of 02:01PM EDT. Market open.
Advertisement

Global Blood Therapeutics, Inc.

181 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 741 7700
https://www.gbt.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees457

Key Executives

NameTitlePayExercisedYear Born
Dr. Ted W. Love M.D.Pres, CEO & Director1.06MN/A1959
Mr. Jeffrey S. FarrowCFO & Principal Accounting Officer672.67kN/A1962
Ms. Jung E. ChoiChief Bus. & Strategy Officer645kN/A1970
Mr. David L. JohnsonChief Commercial Officer661.5kN/A1969
Dr. Kim Smith-Whitley M.D.Exec. VP and Head of R&D654kN/A1961
Dr. David R. PhillipsFounder & AdvisorN/AN/AN/A
Dr. Matthew P. Jacobson Ph.D.Founder & AdvisorN/AN/AN/A
Dr. Andrej Sali Ph.D.Founder & AdvisorN/AN/AN/A
Ms. Nazila HabibizadExec. VP of OperationsN/AN/A1963
Stephanie YaoSr. Director of Corp. Communications & Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Corporate Governance

Global Blood Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 10. The pillar scores are Audit: 4; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement